Incyte wins Priority Review for cholangiocarcinoma therapy

Two months after presenting Phase II data at ESMO, Incyte Corp. (NASDAQ:INCY) said FDA has accepted and granted Priority Review to an NDA for pemigatinib to treat the rare bile duct cancer cholangiocarcinoma. The candidate's PDUFA date is May 30.

Pemigatinib’s target population is patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The candidate is an oral inhibitor of FGFR isoforms 1, 2 and 3...